|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Restoration of wild-type PPP2R1A in P179R-mutant endometrial cancer cells increases phosphatase activity and inhibits tumor growth <i>in vivo</i> Furthermore, a small-molecule activator of PP2A (SMAP) phenocopies restoration of wild-type PPP2R1A to suppress tumor growth.
|
31416848 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, overexpression of PPP2R1A-WT increased cell proliferation in vitro and tumor growth in vivo.
|
27272709 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Multivariate analysis showed that larger tumor size, higher mitotic rate, and PPP2R1A mutation are independent prognostic factors for overall survival; however, PPP2R1A mutation was not an independent prognostic factor for disease-free survival.
|
27469332 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, overexpression of the Aα mutants in EC cells harboring wild-type PPP2R1A increased anchorage-independent growth and tumor formation, and triggered hyperphosphorylation of oncogenic PP2A-B56/B' substrates in the GSK3β, Akt, and mTOR/p70S6K signaling pathways.
|
27485451 |
2016 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, this is the first report describing PPP2R1A mutations in gastric fundic gland-associated neoplasms.
|
25820416 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Of these, 14 were downregulated in primary and metastatic prostate cancer, including two subunits of the protein phosphatase 2 (PP2A) holoenzyme complex: PPP2R1A, a structural subunit with known tumor-suppressor properties in several tumor types; and PPP2R2C, a PP2A substrate-binding regulatory subunit that has not been previously identified as a tumor suppressor.
|
23493267 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Somatic mutations in PPP2R1A, which encodes a scaffolding subunit of serine/threonine protein phosphatase 2A (PP2A), have recently been described in different types of gynecological neoplasias.
|
23267135 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
They are generally indolent, present in stage I (tumor confined to the ovary), and are characterized by specific mutations, including KRAS, BRAF, ERBB2, CTNNB1, PTEN, PIK3CA, ARID1A, and PPP2R1A, which target specific cell signaling pathways.
|
21683865 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
PPP2R1A encodes a scaffolding subunit of a major serine/threonine phosphatase, protein phosphatase 2A (PP2A), which plays a critical role in diverse cellular functions, including negative regulation of cellular proliferation and potential tumour suppression.
|
21432855 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The nature and pattern of the mutations suggest that PPP2R1A functions as an oncogene and ARID1A as a tumor-suppressor gene.
|
20826764 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although overexpression of these mutants failed to render immortalized cells tumorigenic, partial suppression of endogenous PP2A Aalpha expression activated the AKT pathway and permitted cells to form tumors in immunodeficient mice.
|
16166293 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Since PPP2R1A was therefore a compelling candidate for the FWT2 gene, we analysed the coding region of PPP2R1A in DNA and RNA samples from affected members of four Wilms tumor families and 30 sporadic tumors and identified no mutations in PPP2R1A in any of these 34 samples.
|
11360189 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms.
|
10713707 |
2000 |